Search
Rishi S. Kotecha MB ChB (Hons) MRCPCH FRACP PhD Co-Head, Leukaemia Translational Research rishi.kotecha@health.wa.gov.au Co-Head, Leukaemia
Allogeneic hematopoietic stem cell transplant (HSCT) is a proven curative therapy for children with high-risk myeloid malignancies. Disease relapse, transplant-related mortality and graft versus host disease (GvHD) are the main causes of treatment failure and death post-transplant. The optimum pretransplant conditioning regimen is yet to be defined. There is limited data regarding the use of busulfan, fludarabine and melphalan as a myeloablative conditioning regimen in children receiving HSCT for myeloid malignancies.
In this study, we investigate the in vivo synergy between romidepsin and cytarabine
In this review, we discuss the different subsets of tumor-infiltrating dendritic cells and their role in anti-tumor immunity
Our data demonstrate that CD8+XCR1neg DCs possess a unique pattern of endocytic receptors and a restricted TLR profile that is particularly enriched for TLR5
Our findings present a novel mouse model for glioma demonstrating that the PI3K pathway is important for initiation of tumorigenesis
The ANZCHOG-BN is a new biobank network in Australasia that was developed to improve and streamline access to high-quality pediatric and AYA cancer biospecimens
Our findings shed light on the mechanisms of leukemia-induced bone loss
We found two known risk factors in a large cohort of children treated for ALL and identified other factors associated with venous thromboembolism
Our results show that TRM cells have a fundamental role in the surveillance of subclinical melanomas in the skin by maintaining cancer-immune equilibrium